Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib

Saved in:
Bibliographic Details
Main Authors: Chenghao Fu, Haonan Du, Qiang Wang, Weiyou Zhu, Guangli Bian, Zhujuan Zhong, Yuheng Wang, Lei Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1527232/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850158507506008064
author Chenghao Fu
Chenghao Fu
Haonan Du
Qiang Wang
Weiyou Zhu
Guangli Bian
Zhujuan Zhong
Yuheng Wang
Lei Cao
author_facet Chenghao Fu
Chenghao Fu
Haonan Du
Qiang Wang
Weiyou Zhu
Guangli Bian
Zhujuan Zhong
Yuheng Wang
Lei Cao
author_sort Chenghao Fu
collection DOAJ
format Article
id doaj-art-770fc02317c6488fb25f7b09197af0bc
institution OA Journals
issn 1664-3224
language English
publishDate 2024-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-770fc02317c6488fb25f7b09197af0bc2025-08-20T02:23:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-11-011510.3389/fimmu.2024.15272321527232Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with AnlotinibChenghao Fu0Chenghao Fu1Haonan Du2Qiang Wang3Weiyou Zhu4Guangli Bian5Zhujuan Zhong6Yuheng Wang7Lei Cao8Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Thoracic Surgery, Taizhou Fourth People’s Hospital, Taizhou, Jiangsu, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Radiology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, ChinaDepartment of Pathology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Oncology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, Chinahttps://www.frontiersin.org/articles/10.3389/fimmu.2024.1527232/fulltail effectimmunotherapycancer therapyPSCICISintilimab
spellingShingle Chenghao Fu
Chenghao Fu
Haonan Du
Qiang Wang
Weiyou Zhu
Guangli Bian
Zhujuan Zhong
Yuheng Wang
Lei Cao
Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
Frontiers in Immunology
tail effect
immunotherapy
cancer therapy
PSC
ICI
Sintilimab
title Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
title_full Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
title_fullStr Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
title_full_unstemmed Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
title_short Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
title_sort corrigendum case report a golden tail of immunotherapy significant tail effect in a chemotherapy resistant advanced pulmonary sarcomatoid carcinoma patient treated by sintilimab combined with anlotinib
topic tail effect
immunotherapy
cancer therapy
PSC
ICI
Sintilimab
url https://www.frontiersin.org/articles/10.3389/fimmu.2024.1527232/full
work_keys_str_mv AT chenghaofu corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT chenghaofu corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT haonandu corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT qiangwang corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT weiyouzhu corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT guanglibian corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT zhujuanzhong corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT yuhengwang corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib
AT leicao corrigendumcasereportagoldentailofimmunotherapysignificanttaileffectinachemotherapyresistantadvancedpulmonarysarcomatoidcarcinomapatienttreatedbysintilimabcombinedwithanlotinib